Interstice Therapeutics

Interstice Therapeutics is a private, early-stage biotech founded in 2021 and based in Cambridge, MA, operating at the intersection of ophthalmology and drug delivery. The company employs a capital-efficient 505(b)(2) regulatory strategy to develop modified versions of approved drugs, targeting specific adoption gaps in the market. This approach is designed to reduce clinical development time and risk compared to novel New Drug Applications (NDAs). As a pre-revenue company, its success hinges on advancing its pipeline through clinical development and securing strategic partnerships or funding.

Strategic application of the 505(b)(2) regulatory pathway combined with drug delivery and formulation science to develop improved versions of approved therapies.

Competition is fierce in ophthalmology, particularly from giants like Regeneron, Roche, and Novartis, who are advancing their own longer-acting formulations and novel mechanisms. Interstice also competes with other biotechs pursuing 505(b)(2) strategies in the same space. Success will require demonstrating clear differentiation in efficacy, safety, or convenience over both the reference product and other emerging therapies.